Quantum Cat FeLV

Country: Велика Британија

Језик: Енглески

Извор: VMD (Veterinary Medicines Directorate)

Активни састојак:

Feline leukemia virus

Доступно од:

Intervet UK Ltd

АТЦ код:

QI06AA01

INN (Међународно име):

Feline leukemia virus

Статус ауторизације:

Expired

Карактеристике производа

Revised: December 2010
AN: 01891/2009
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Quantum Cat FeLV
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
PER ML
Inactivated sub-unit antigens
(gp 70 and FOCMA) of feline leukaemia
virus (FeLV) sub-types A, B and C: _minimum_: 2266 ng of gp70 antigen.
ADJUVANTS
Alhydrogel 2 % Al
2
0
3
50 μl
Quil A
25 μg
EXCIPIENTS
Thiomersal (Preservative)
0.115 mg (maximum)
For a full list of excipients see section 6.1
3.
PHARMACEUTICAL FORM
Solution for injection.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats from 9 weeks of age.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Active immunization of cats to reduce persistent viraemia and lymphoid
tumours
caused by FeLV infection, and thereby to reduce other diseases
associated with
FeLV infection.
Onset of immunity occurs by approximately 3 weeks after the last dose
of the Basic
Vaccination Scheme.
The duration of immunity is at least 12 months.
4.3
CONTRA-INDICATIONS
Unhealthy animals should not be vaccinated.
The use of immunosuppressant drugs or procedures within one month of
vaccination is contra-indicated.
Page 1 of 4
Revised: December 2010
AN: 01891/2009
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
If an anaphylactic reaction occurs, institute treatment according to
the clinical signs
using adrenaline or other appropriate medication.
Vaccination is of no known clinical value in cats with pre-existing
FeLV infection, nor
will it change the natural course of the disease.
The effect of maternally derived antibodies (MDA) on the response to
vaccination is
not known, but on the basis of published data and field use it is
expected that the
levels of MDA that will be present at 9 weeks of age will not
interfere with the
response to vaccination.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
None
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY
MEDICINAL PRODUCT TO ANIMALS
In case of accidental self-injection, wash the area immedia